AbCellera, a biotechnology company based in Vancouver, British Columbia, has announced that it will present data from its Phase 1/2 clinical trial for the drug candidate ABCL635 at The Menopause Society’s upcoming 2026 Annual Meeting. This annual meeting is set to take place from October 20 to 24, 2026, at the Hilton Bayfront in San Diego, California. During this event, researchers and industry professionals gather to discuss advancements and research in menopause-related health issues.
The presentation will include detailed findings related to the safety and pharmacokinetics of ABCL635, which is being investigated for its potential therapeutic benefits. AbCellera's announcement highlights the company's commitment to advancing research in the field and providing valuable insights into new treatment options for women experiencing menopause. The conference is expected to attract a variety of stakeholders, including healthcare providers, researchers, and industry leaders who are focused on women's health.
This presentation will mark an important milestone for AbCellera as it continues to develop its innovative therapies and participate in significant scientific discussions. Details regarding the specific content of the poster and data presentation are anticipated to be shared closer to the event date.
Analyzed Canadian Outlets (1)
1 headline